Considering previous studies which demonstrated the potential pharmacogenetic roles for genetic variants of DDR pathways in AML [11–14], we also investigate the association of RAD51 rs1801320, XRCC3 rs861539, NBS1 rs1805794, MRE11 rs569143, RAD50 rs2299014 variants with AML outcomes. The gene discussed is XRCC3; the disease is acute myeloid leukemia.